Our study focused on the effect and underlying mechanism of DM on CRC and our findings indicated opportunities for BMP4 as a novel therapeutic target to reduce metastatic burden in patients and provided evidence that GLP-1RA could be safely used for CRC patients with comorbidity of diabetes. This evidence concerns the gene BMP4 and diabetes mellitus.